Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

TP53 mutation + Chr del(17p)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

FGF19 amplification + HRAS Q61R + TP53 672+2T>G (6)

FGF3 amplification + HRAS Q61R + TP53 672+2T>G (6)

FGF4 amplification + HRAS Q61R + TP53 672+2T>G (6)

EML4-ALK variant 3 + TP53 mutation (5)

TP53 mutation + ALK positive (4)

BRCA wild-type + TP53 mutation (3)

TP53 mutation + Chr del(11q) (3)

ALK fusion + TP53 mutation (2)

EGFR exon 19 deletion + TP53 mutation + RB1 mutation (2)

EML4-ALK fusion + TP53 mutation (2)

HR positive + TP53 mutation (2)

ALK fusion + EML4-ALK variant 3 + TP53 mutation (1)

ALK negative + TP53 deletion (1)

ALK positive + EML4-ALK fusion + TP53 mutation (1)

CD74-ROS1 fusion + TP53 mutation (1)

CPE-ALK fusion + TP53 wild-type (1)

Chr del(5q) + TP53 expression (1)

Chr t(11;14) + TP53 mutation (1)

EGFR exon 19 deletion + EGFR exon 21 mutation + TP53 mutation (1)

EGFR exon 19 deletion + TP53 mutation + CDK6 amplification + KRAS amplification (1)

EGFR exon 19 deletion + TP53 mutation + MET amplification (1)

EGFR exon 20 insertion + TP53 mutation (1)

EGFR expression + TP53 mutation (1)

EGFR mutation + MET amplification + TP53 mutation (1)

EGFR mutation + PD-L1 expression + TP53 mutation (1)

EGFR mutation + TP53 expression (1)

FAT1 mutation + TP53 wild-type (1)

FLT3 wild-type + TP53 mutation (1)

FLT3-ITD mutation + MLL fusion + TP53 mutation (1)

GNA13 deletion + TP53 mutation (1)

HER-2 positive + TP53 mutation (1)

HRAS Q61R + TP53 P278S + PD-L1 overexpression (1)

IDH wild-type + FGFR3 S249C + TP53 V73fs (1)

IDH1 mutation + ATRX deletion + TP53 deletion (1)

KDR amplification + FLT4 amplification + MCL1 amplification + TP53 R213 + TP53 H179Y + ARID1A Q2128 (1)

KIF5B-RET fusion + TP53 H193R + MYC amplification (1)

KRAS G12D + TP53 deletion (1)

KRAS mutation + TP53 mutation + GNA13 deletion (1)

KRAS mutation + TP53 mutation + PD-L1 expression + PD-1 expression (1)

LDH elevation + TP53 mutation (1)

LRP1B mutation + TP53 wild-type (1)

MDM2 amplification + TP53 wild-type (1)

MDM2 amplification + TP53 wild-type + TWIST1 amplification (1)

MET amplification + TP53 mutation (1)

MET amplification + TP53 mutation + SMAD4 mutation + CTNNA1 mutation (1)

MSI-H/dMMR + TP53 mutation (1)

MSLN overexpression + TP53 mutation (1)

PD-L1 overexpression + KRAS G12C + TP53 mutation (1)

PD-L1 overexpression + RET-KIF5B fusion + TP53 mutation + AR mutation + RET rearrangement (1)

ROS1 fusion + TP53 mutation (1)

ROS1-CD74 fusion + TP53 K139N (1)

SQSTM1-NTRK1 + PIK3CA E545K + TP53 L145R + PD-L1 overexpression (1)

STK11 mutation + KRAS mutation + TP53 deletion (1)

TMB-H + RB1 L518fs*6 + ERCC4 R799W + TP53 C124* (1)

TMEM87A-RASGRF1 fusion + TP53 R273H (1)

TP53 R280K + BRCA wild-type (1)

TP53 S12F + KRAS G12D + TMB-L (1)

TP53 deletion + RB1 deletion + CTSK expression (1)

TP53 mutation + FANCM mutation + TMB-H (1)

TP53 mutation + FGFR2 fusion (1)

TP53 mutation + LRP1B mutation + TMB-H (1)

TP53 mutation + MET amplification + PD-L1 overexpression (1)

TP53 mutation + PD-L1 expression (1)

TP53 mutation + PD-L1 negative (1)

TP53 mutation + TMB-H + PD-L1 overexpression (1)

TP53 wild-type + ER positive (1)

FGFR2 K660N + TP53 deletion (0)

FGF19 amplification + HRAS Q61R + TP53 672+2T>G (6)

FGF3 amplification + HRAS Q61R + TP53 672+2T>G (6)

FGF4 amplification + HRAS Q61R + TP53 672+2T>G (6)

EML4-ALK variant 3 + TP53 mutation (5)

TP53 mutation + ALK positive (4)

BRCA wild-type + TP53 mutation (3)

TP53 mutation + Chr del(11q) (3)

ALK fusion + TP53 mutation (2)

EGFR exon 19 deletion + TP53 mutation + RB1 mutation (2)

EML4-ALK fusion + TP53 mutation (2)

HR positive + TP53 mutation (2)

ALK fusion + EML4-ALK variant 3 + TP53 mutation (1)

ALK negative + TP53 deletion (1)

ALK positive + EML4-ALK fusion + TP53 mutation (1)

CD74-ROS1 fusion + TP53 mutation (1)

CPE-ALK fusion + TP53 wild-type (1)

Chr del(5q) + TP53 expression (1)

Chr t(11;14) + TP53 mutation (1)

EGFR exon 19 deletion + EGFR exon 21 mutation + TP53 mutation (1)

EGFR exon 19 deletion + TP53 mutation + CDK6 amplification + KRAS amplification (1)

EGFR exon 19 deletion + TP53 mutation + MET amplification (1)

EGFR exon 20 insertion + TP53 mutation (1)

EGFR expression + TP53 mutation (1)

EGFR mutation + MET amplification + TP53 mutation (1)

EGFR mutation + PD-L1 expression + TP53 mutation (1)

EGFR mutation + TP53 expression (1)

FAT1 mutation + TP53 wild-type (1)

FLT3 wild-type + TP53 mutation (1)

FLT3-ITD mutation + MLL fusion + TP53 mutation (1)

GNA13 deletion + TP53 mutation (1)

HER-2 positive + TP53 mutation (1)

HRAS Q61R + TP53 P278S + PD-L1 overexpression (1)

IDH wild-type + FGFR3 S249C + TP53 V73fs (1)

IDH1 mutation + ATRX deletion + TP53 deletion (1)

KDR amplification + FLT4 amplification + MCL1 amplification + TP53 R213 + TP53 H179Y + ARID1A Q2128 (1)

KIF5B-RET fusion + TP53 H193R + MYC amplification (1)

KRAS G12D + TP53 deletion (1)

KRAS mutation + TP53 mutation + GNA13 deletion (1)

KRAS mutation + TP53 mutation + PD-L1 expression + PD-1 expression (1)

LDH elevation + TP53 mutation (1)

LRP1B mutation + TP53 wild-type (1)

MDM2 amplification + TP53 wild-type (1)

MDM2 amplification + TP53 wild-type + TWIST1 amplification (1)

MET amplification + TP53 mutation (1)

MET amplification + TP53 mutation + SMAD4 mutation + CTNNA1 mutation (1)

MSI-H/dMMR + TP53 mutation (1)

MSLN overexpression + TP53 mutation (1)

PD-L1 overexpression + KRAS G12C + TP53 mutation (1)

PD-L1 overexpression + RET-KIF5B fusion + TP53 mutation + AR mutation + RET rearrangement (1)

ROS1 fusion + TP53 mutation (1)

ROS1-CD74 fusion + TP53 K139N (1)

SQSTM1-NTRK1 + PIK3CA E545K + TP53 L145R + PD-L1 overexpression (1)

STK11 mutation + KRAS mutation + TP53 deletion (1)

TMB-H + RB1 L518fs*6 + ERCC4 R799W + TP53 C124* (1)

TMEM87A-RASGRF1 fusion + TP53 R273H (1)

TP53 R280K + BRCA wild-type (1)

TP53 S12F + KRAS G12D + TMB-L (1)

TP53 deletion + RB1 deletion + CTSK expression (1)

TP53 mutation + FANCM mutation + TMB-H (1)

TP53 mutation + FGFR2 fusion (1)

TP53 mutation + LRP1B mutation + TMB-H (1)

TP53 mutation + MET amplification + PD-L1 overexpression (1)

TP53 mutation + PD-L1 expression (1)

TP53 mutation + PD-L1 negative (1)

TP53 mutation + TMB-H + PD-L1 overexpression (1)

TP53 wild-type + ER positive (1)

FGFR2 K660N + TP53 deletion (0)

›

TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2
TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	venetoclax + rituximab Sensitive: A2 - Guideline venetoclax + rituximab Sensitive : A2	venetoclax + rituximab Sensitive: A2 - Guideline venetoclax + rituximab Sensitive : A2
TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	zanubrutinib Sensitive: A2 - Guideline zanubrutinib Sensitive : A2	zanubrutinib Sensitive: A2 - Guideline zanubrutinib Sensitive : A2
TP53 mutation + Chr del(17p)	Small Lymphocytic Lymphoma	TP53 mutation + Chr del(17p)	Small Lymphocytic Lymphoma	pirtobrutinib Sensitive: C3 – Early Trials pirtobrutinib Sensitive : C3	pirtobrutinib Sensitive: C3 – Early Trials pirtobrutinib Sensitive : C3
TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	pirtobrutinib Sensitive: C3 – Early Trials pirtobrutinib Sensitive : C3	pirtobrutinib Sensitive: C3 – Early Trials pirtobrutinib Sensitive : C3
TP53 mutation + Chr del(17p)	Small Lymphocytic Lymphoma	TP53 mutation + Chr del(17p)	Small Lymphocytic Lymphoma	orelabrutinib Sensitive: C3 – Early Trials orelabrutinib Sensitive : C3	orelabrutinib Sensitive: C3 – Early Trials orelabrutinib Sensitive : C3
TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	orelabrutinib Sensitive: C3 – Early Trials orelabrutinib Sensitive : C3	orelabrutinib Sensitive: C3 – Early Trials orelabrutinib Sensitive : C3
TP53 mutation + Chr del(17p)	Acute Myelogenous Leukemia	TP53 mutation + Chr del(17p)	Acute Myelogenous Leukemia	MGD006 Sensitive: C3 – Early Trials MGD006 Sensitive : C3	MGD006 Sensitive: C3 – Early Trials MGD006 Sensitive : C3
TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	venetoclax + ibrutinib + obinutuzumab Sensitive: C3 – Early Trials venetoclax + ibrutinib + obinutuzumab Sensitive : C3	venetoclax + ibrutinib + obinutuzumab Sensitive: C3 – Early Trials venetoclax + ibrutinib + obinutuzumab Sensitive : C3
TP53 mutation + Chr del(17p)	Small Lymphocytic Lymphoma	TP53 mutation + Chr del(17p)	Small Lymphocytic Lymphoma	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3
TP53 mutation + Chr del(17p)	Small Lymphocytic Lymphoma	TP53 mutation + Chr del(17p)	Small Lymphocytic Lymphoma	venetoclax + ibrutinib Sensitive: C3 – Early Trials venetoclax + ibrutinib Sensitive : C3	venetoclax + ibrutinib Sensitive: C3 – Early Trials venetoclax + ibrutinib Sensitive : C3
TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	venetoclax + ibrutinib Sensitive: C3 – Early Trials venetoclax + ibrutinib Sensitive : C3	venetoclax + ibrutinib Sensitive: C3 – Early Trials venetoclax + ibrutinib Sensitive : C3
TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	epcoritamab-bysp Sensitive: C3 – Early Trials epcoritamab-bysp Sensitive : C3	epcoritamab-bysp Sensitive: C3 – Early Trials epcoritamab-bysp Sensitive : C3
TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	TP53 mutation + Chr del(17p)	Chronic Lymphocytic Leukemia	obinutuzumab + acalabrutinib Sensitive: C3 – Early Trials obinutuzumab + acalabrutinib Sensitive : C3	obinutuzumab + acalabrutinib Sensitive: C3 – Early Trials obinutuzumab + acalabrutinib Sensitive : C3